ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 16 2024
0mins
Source: Newsfilter
Acquisition Impact: ANI Pharmaceuticals has completed the acquisition of Alimera Sciences, significantly strengthening its Rare Disease segment and adding approximately $105 million in projected revenue for 2024, while also enhancing its presence in ophthalmology with two durable commercial products, ILUVIEN® and YUTIQ®.
Financial Strategy: The new capital structure established by ANI is expected to reduce annual interest expenses by about $39 million, providing financial flexibility to support the integration of Alimera and ongoing growth initiatives.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
